Doctors switched colonoscopy prep formulas because the older ones were either dangerous or so miserable to drink that patients skipped their screenings altogether. The most dramatic change came in December 2008, when the FDA announced that oral sodium phosphate products — most notably Fleet Phospho-soda — could cause acute phosphate nephropathy, a form of severe kidney damage sometimes requiring dialysis or even a kidney transplant. C.B. Fleet Company voluntarily recalled the product, but the FDA had actually flagged kidney failure and death risks as early as 2001. Twenty-one cases of severe kidney injury were identified before the recall finally happened. That seven-year gap between the first warning and the recall is worth remembering for anyone who assumes that a product on pharmacy shelves has been thoroughly vetted.
But kidney damage was only part of the story. The other half was compliance. The traditional gold-standard prep, GoLYTELY, requires patients to drink four liters of a polyethylene glycol electrolyte solution — roughly a gallon of salty, chemical-tasting liquid. Only about 66 percent of patients manage to finish the full volume. When a third of your patients cannot complete the prep, the colonoscopy itself becomes less reliable, and some patients simply refuse to schedule the procedure at all. These twin pressures — safety and tolerability — drove a wholesale shift toward low-volume preps, tablet options, and updated dietary guidelines that are still reshaping how gastroenterologists prepare patients today. This article covers the specific drug changes that have occurred over the past two decades, the newer alternatives now available, the landmark 2025 guideline update, the cost barriers that complicate access to better preps, and what all of this means for people with dementia or other conditions that make colonoscopy prep especially challenging.
Table of Contents
- What Drove the Major Colonoscopy Prep Drug Changes Over the Past Two Decades?
- How Tablet-Form Preps Changed the Colonoscopy Landscape
- The 2025 Guideline Update and What It Means for Patients with Dementia
- Comparing Cost and Access Across Colonoscopy Prep Options
- Why Colonoscopy Prep Is Especially Risky for Dementia Patients
- How Caregivers Can Advocate for Better Prep Protocols
- Where Colonoscopy Prep Is Heading
- Conclusion
- Frequently Asked Questions
What Drove the Major Colonoscopy Prep Drug Changes Over the Past Two Decades?
The timeline of colonoscopy prep evolution is essentially a story of the medical establishment catching up with what patients had been saying for years: the old preps were intolerable. Fleet Phospho-soda was popular precisely because it was a low-volume alternative to GoLYTELY — patients only had to drink a small amount of liquid. But the sodium phosphate in the formula could cause dangerous electrolyte shifts, particularly in older adults, people with kidney disease, and those taking certain blood pressure medications. When the FDA finally issued the recall in 2008, gastroenterologists lost one of their few patient-friendly options and were temporarily pushed back toward the four-liter jug that nobody wanted to drink. That setback actually accelerated innovation. Pharmaceutical companies recognized a massive gap in the market: patients needed something that was both safe and tolerable. The result was a wave of new formulations over the following decade.
MoviPrep cut the PEG volume to two liters. Suprep introduced a sulfate-based solution in two small bottles. And in 2018, the FDA approved PLENVU, a one-liter PEG-based prep by Salix Pharmaceuticals — the lowest total-volume bowel prep currently available in the United States. Phase 3 clinical trials showed PLENVU was as effective as both Suprep and MoviPrep at cleansing the bowel, while requiring patients to drink significantly less liquid. The comparison is stark. A patient prepping with GoLYTELY faces a gallon of fluid. A patient prepping with PLENVU faces roughly a quarter of that volume. For elderly patients, especially those with cognitive impairment who may struggle to follow complex multi-step instructions, that difference can determine whether a colonoscopy happens at all.
How Tablet-Form Preps Changed the Colonoscopy Landscape
On November 10, 2020, the FDA approved SUTAB — the first tablet-form colonoscopy prep to reach the market in over a decade. Developed by Sebela Pharmaceuticals and Braintree Laboratories, SUTAB consists of 24 sulfate-based tablets taken in two doses of 12 tablets each, along with water. For patients who gag on liquid preps or simply cannot tolerate the taste, tablets represented a fundamentally different experience. The clinical data backed up the enthusiasm. In trials, 92 percent of patients using SUTAB achieved successful colon cleansing, compared to 89 percent for MoviPrep. When compared head-to-head with Suprep, adequate prep was achieved in 98.1 percent of SUTAB patients versus 93.8 percent for Suprep. That compliance rate of 98 percent with sulfate-based tablets versus 66 percent with four-liter PEG solutions tells you everything about why the industry moved in this direction.
However, if a patient has difficulty swallowing pills — common in older adults with dysphagia or advanced dementia — tablets may not be the answer. Caregivers should discuss swallowing ability with the prescribing physician before assuming SUTAB is the easier option. A pill-based prep is only better if the patient can actually take the pills. There is also a timing consideration. SUTAB requires patients to drink a substantial amount of water alongside the tablets, so the total fluid intake is not negligible. Patients who hear “tablet prep” and assume they can skip the liquids entirely are in for a surprise. The tablets replace the unpleasant-tasting solution, not the hydration requirement.
The 2025 Guideline Update and What It Means for Patients with Dementia
In March 2025, the U.S. Multi-Society Task Force on Colorectal Cancer published its first updated consensus recommendations for colonoscopy prep since 2014 — an eleven-year gap. Published in the journal Gastroenterology, these guidelines reflected over a decade of new evidence and shifted several longstanding practices. Two-liter split-dose regimens are now recommended as sufficient for average-risk patients, officially retiring the four-liter standard for most people. Dietary restrictions were limited to the day before the colonoscopy only, with patients allowed clear liquids or a low-fiber, low-residue diet for early and midday meals. Same-day prep was accepted as an alternative for afternoon colonoscopies.
And simethicone was suggested as an adjunctive measure to reduce gas and improve visualization. The guidelines also set a quality benchmark: endoscopists and endoscopy units should target greater than 90 percent adequate bowel prep rates. That target acknowledges what the data has long shown — that inadequate prep leads to missed polyps, repeat procedures, and higher long-term cancer risk. Here is the critical caveat for readers of this site: the relaxed regimens explicitly do not apply to patients with dementia. The guidelines single out dementia alongside constipation, motility-slowing medications, cirrhosis, Parkinson’s disease, and diabetes as conditions requiring more intensive or individualized prep protocols. This means that while the general population benefits from simpler, shorter prep routines, dementia patients and their caregivers should not assume these lighter protocols apply to them. A person with moderate Alzheimer’s disease who also takes an anticholinergic medication that slows gut motility may need the full traditional prep — or a customized plan developed with their gastroenterologist and neurologist working together.
Comparing Cost and Access Across Colonoscopy Prep Options
The shift toward better-tolerated preps has introduced a significant equity problem. According to a Medscape analysis, the median out-of-pocket cost for low-volume colonoscopy preps is approximately 60 dollars under commercial insurance plans, compared to just 10 dollars for high-volume preparations like generic GoLYTELY, which typically costs between 15 and 40 dollars. SUTAB runs about 145 dollars, while Suprep comes in around 35 dollars. The most tolerable options are, in many cases, the least affordable. This creates a troubling dynamic for colonoscopy screening uptake.
If a patient hears that a newer, easier prep exists but then learns their insurance will not cover it — or covers it with a high copay — they may decide to skip the colonoscopy entirely rather than face the cheaper but more grueling alternative. For dementia caregivers managing tight budgets alongside mounting care costs, a 145-dollar prep bill on top of the colonoscopy itself can feel like a bridge too far. The tradeoff is real: generic GoLYTELY at 15 dollars requires drinking a gallon of solution that most patients struggle to finish, while SUTAB at 145 dollars offers a nearly 98 percent compliance rate in tablet form. The question becomes whether the higher cost is justified by the dramatically better chance of actually completing the prep — and by extension, getting a reliable screening. Some insurance plans are beginning to cover newer preps more generously, particularly as evidence mounts that inadequate prep leads to costly repeat procedures. But coverage remains inconsistent, and patients should check with their insurer before assuming a specific prep will be affordable.
Why Colonoscopy Prep Is Especially Risky for Dementia Patients
The risks of colonoscopy prep extend beyond inconvenience for people living with dementia. Dehydration is the most immediate concern. All colonoscopy preps work by flushing the colon, which means significant fluid loss. A person with dementia may not recognize thirst, may refuse to drink replacement fluids, or may not understand why they are being asked to consume unusual liquids. Severe dehydration in an elderly person with compromised kidney function — a common comorbidity in dementia patients — can trigger acute kidney injury, confusion that mimics or worsens dementia symptoms, and dangerous electrolyte imbalances. The 2008 Fleet Phospho-soda recall is a cautionary tale that remains relevant.
While that specific product is off the market, the underlying lesson holds: bowel prep agents that alter electrolyte balance pose heightened risks for older adults with reduced renal function. Even the newer, safer preparations require careful hydration monitoring. Caregivers should track fluid intake and output during the prep period and watch for signs of excessive dehydration, including dark urine, dizziness, rapid heartbeat, or sudden worsening of confusion. There is also the question of whether a colonoscopy is appropriate at all. For a patient with advanced dementia and a limited life expectancy, the risks and burdens of both the prep and the procedure may outweigh the potential benefits of cancer screening. This is a conversation that families should have with the patient’s care team well before a colonoscopy is scheduled — not in the gastroenterologist’s office the week before the procedure.
How Caregivers Can Advocate for Better Prep Protocols
A caregiver accompanying a dementia patient through colonoscopy prep should arrive at the gastroenterology appointment with specific questions. Ask which prep formulation the doctor recommends and why. Ask whether a low-volume option like PLENVU or a tablet option like SUTAB is appropriate given the patient’s swallowing ability and cognitive status. Ask whether the 2025 relaxed dietary guidelines apply or whether the patient’s condition requires a more intensive protocol.
One practical strategy that some caregivers have found helpful is requesting a split-dose prep with the second dose timed for early morning rather than the middle of the night. Sleep disruption can significantly worsen confusion and behavioral symptoms in dementia patients, and a 4 a.m. wake-up for prep can derail an already fragile routine. If the colonoscopy is scheduled for the afternoon, ask whether same-day prep — now accepted under the 2025 guidelines for average-risk patients — might be adapted for your situation, understanding that the doctor may determine it is not suitable for someone with a motility-affecting condition.
Where Colonoscopy Prep Is Heading
The global colonoscopy bowel prep drug market is projected to reach 2.5 billion dollars by 2025, growing at a 5 percent compound annual growth rate through 2033. That growth signals continued pharmaceutical investment in developing even more tolerable formulations. Research is ongoing into ultra-low-volume preps, preps that can be taken entirely as pills without supplemental water loading, and preps tailored for specific patient populations — including older adults with cognitive impairment.
The 2025 guideline update, while explicitly excluding dementia patients from its relaxed protocols, may indirectly benefit them by pushing the field toward an expectation that prep should be simpler and more patient-centered. As the standard of care for the general population moves toward two-liter split-dose regimens and same-day options, the pressure will mount to develop equivalent improvements for higher-risk groups. For families navigating dementia care, the message is cautiously optimistic: colonoscopy prep is getting better, but the improvements have not yet fully reached the patients who need them most.
Conclusion
The evolution of colonoscopy prep drugs over the past two decades reflects a field that has been forced to reckon with its own shortcomings — dangerous formulations that stayed on the market too long, prep volumes that most patients could not finish, and guidelines that went eleven years without an update. The shift from Fleet Phospho-soda to GoLYTELY to PLENVU and SUTAB represents genuine progress, with compliance rates climbing from 66 percent to over 98 percent in some studies. The 2025 Multi-Society Task Force guidelines codified many of these advances into standard practice, though they were careful to note that patients with dementia, Parkinson’s disease, and other conditions require individualized protocols. For caregivers and families, the practical takeaway is to be an active participant in the prep decision.
Do not assume the gastroenterologist is aware of all the patient’s medications, cognitive limitations, and swallowing difficulties. Ask about low-volume and tablet options. Discuss cost and insurance coverage before the prescription is written. And for patients with advanced dementia, have an honest conversation about whether the colonoscopy itself is still in the patient’s best interest. The prep drugs have gotten better, but the decision about whether to use them at all remains deeply personal.
Frequently Asked Questions
What is the easiest colonoscopy prep for elderly patients?
PLENVU is currently the lowest-volume liquid prep at just one liter, while SUTAB offers a tablet alternative with 24 pills taken in two doses. However, the best option depends on the patient’s ability to swallow pills, kidney function, and other medications. Patients with dementia or Parkinson’s disease may need a customized protocol rather than a standard low-volume prep.
Why was Fleet Phospho-soda recalled?
The FDA recalled Fleet Phospho-soda in December 2008 after identifying 21 cases of acute phosphate nephropathy — severe kidney damage that in some cases required dialysis or transplant. The sodium phosphate in the formula caused dangerous electrolyte shifts, particularly in older adults and those with existing kidney issues. The FDA had actually flagged these risks as early as 2001.
How much does colonoscopy prep cost out of pocket?
Costs vary widely. Generic GoLYTELY runs 15 to 40 dollars. Suprep costs approximately 35 dollars. SUTAB is about 145 dollars. The median out-of-pocket cost for low-volume preps under commercial insurance is around 60 dollars, compared to about 10 dollars for high-volume options. Check with your insurer before assuming coverage.
Do the 2025 colonoscopy prep guidelines apply to dementia patients?
No. The 2025 Multi-Society Task Force guidelines explicitly exclude patients with dementia, constipation, motility-slowing medications, cirrhosis, Parkinson’s disease, and diabetes from the relaxed prep protocols. These patients require individualized preparation plans developed with their healthcare team.
Can you do colonoscopy prep with just tablets and no liquid?
SUTAB is a tablet-form prep, but it still requires drinking a significant amount of water alongside the tablets. There is currently no approved colonoscopy prep that eliminates fluid intake entirely. The tablets replace the unpleasant-tasting solution but not the hydration requirement.
